Inovio Pharmaceuticals (INO) PT Lowered to $8 at Roth Capital, Following Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $0.60 -22.08%
Rating Summary:
11 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
11 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Roth Capital analyst Jonathan Aschoff lowered the price target on Inovio Pharmaceuticals (NASDAQ: INO) to $8.00 (from $11.00) while maintaining a Sell rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $350 at Freedom Broker
- Eli Lilly (LLY) PT Raised to $1,600 at Freedom Broker
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
